Q1 2026
Released Aug 11, 2025, before the open
10-Q filed Aug 11, 2025, 42 days after period end · 0001764013-25-000129
Q1 2026 · 10-Q
Revenue—
Net Income-$120.61M-$120.61M N/M vs Q1 2025N/M vs Q4 2025
EPS Diluted-$0.71-$0.71 N/M vs Q1 2025no prior Q4 2025 on file
Operating Cash Flow-$117,411,000N/M
Free Cash Flowderived-$117,411,000N/M
What the release said
The release
Same quarter
| Metric | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 |
|---|---|---|---|---|
| Net Income | -$120.61M | -$87.15M | -$73.94M | -$40.37M |
| EPS Diluted | -$0.71 | -$0.60 | -$0.57 | -$0.35 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Immunovant, Inc. · CIK 1764013 · Engraved from SEC EDGAR